Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Total Current Liabilities for 7 consecutive years, with $64.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities rose 10.03% year-over-year to $64.9 million, compared with a TTM value of $64.9 million through Sep 2025, up 10.03%, and an annual FY2024 reading of $41.7 million, up 104.5% over the prior year.
  • Total Current Liabilities was $64.9 million for Q3 2025 at Summit Therapeutics, up from $60.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $140.2 million in Q2 2024 and bottomed at $11.9 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $43.4 million, with a median of $25.6 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities tumbled 68.89% in 2022, then surged 1074.82% in 2024.
  • Year by year, Total Current Liabilities stood at $25.6 million in 2021, then soared by 51.36% to $38.8 million in 2022, then crashed by 47.39% to $20.4 million in 2023, then skyrocketed by 104.5% to $41.7 million in 2024, then skyrocketed by 55.59% to $64.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for SMMT at $64.9 million in Q3 2025, $60.3 million in Q2 2025, and $34.9 million in Q1 2025.